 Kura Oncology, Inc. KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical outcome data from its RUN-HN study, a Phase 2 open-label, single-arm trial of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma HNSCC whose disease had progressed after prior therapy. A copy of the presentation is available on Kuras website at 